Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437815 | 0.72 | SMN1; SMN2 (0.37) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL5960474 | 0.71 | SMN1; SMN2 (0.35) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL4528112 | 0.71 | HSD17B10 (0.37) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL22250152 | 0.69 | LMNA (0.39) | KDM4EALDH1A1LMNAMAPTHSD17B10 | |
| SCHEMBL8616898 | 0.68 | DDR1 (0.40) | KDM4EMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL4528040 | 0.67 | ALDH1A1 (0.41) | PIK3CGKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL5486555 | 0.64 | HTT (0.38) | MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL11530011 | 0.64 | ELANE (0.45) | PIK3CGKDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL16440380 | 0.63 | CYP1A2 (0.40) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL20646882 | 0.63 | GAA (0.69) | KDM4EALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | PIK3CG 1821/4885KDM4E 3178/4885ALDH1A1 866/4885 |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | PIK3CG 1821/4885KDM4E 3178/4885ALDH1A1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.